Otsuka’s ADHD drug reduces symptoms in Phase IIIb trial
Otsuka’s ADHD drug centanafadine is currently under review by the US FDA, with a PDUFA date of 24 July 2026.
Therapy Area
Corxel to advance oral obesity drug to Phase III trials
Risk of death from cervical cancer is now almost zero with HPV vaccine
MSD’s anti-TL1A mAb from $10.8bn acquisition wins in Phase III trial
Novocure’s Optune Gio fails to show benefit at earlier stage
Placental abruption could increase risk of cardiovascular disease in women
Verastem Oncology’s pancreatic cancer combo shows 86% OS rate
EHA26: BTK combos in CLL/SLL showing earlier line promise
